Market Cap : 3.8 B | Enterprise Value : 4.29 B | PE Ratio : At Loss | PB Ratio : 7.28 |
---|
NAS:GH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:GH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the three months ended in Mar. 2022, Guardant Health paid $0.0 Mil more to buy back shares than it received from issuing new shares. It spent $0.0 Mil paying down its debt. It paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.0 Mil from paying cash dividends to shareholders. It received $0.0 Mil on other financial activities. In all, Guardant Health spent $0.0 Mil on financial activities for the three months ended in Mar. 2022.
The historical data trend for Guardant Health's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Guardant Health's Cash from Financing for the fiscal year that ended in Dec. 2021 is calculated as:
Cash Flow from Financing | (A: Dec. 2021 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 0 | + | 0 | + | -0.146 | + | 0 | + | 0 | + | -66.678 |
= | -66.8 |
Guardant Health's Cash from Financing for the quarter that ended in Mar. 2022 is:
Cash Flow from Financing | (Q: Mar. 2022 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 0 | + | 0 | + | -0.018 | + | 0 | + | 0 | + | 0.006 |
= | -0.0 |
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Guardant Health's issuance of stock for the three months ended in Mar. 2022 was $0.0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Guardant Health's repurchase of stock for the three months ended in Mar. 2022 was $0.0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Guardant Health's net issuance of debt for the three months ended in Mar. 2022 was $-0.0 Mil. Guardant Health spent $0.0 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Guardant Health's net issuance of preferred for the three months ended in Mar. 2022 was $0.0 Mil. Guardant Health paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Guardant Health's cash flow for dividends for the three months ended in Mar. 2022 was $0.0 Mil. Guardant Health received $0.0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Guardant Health's other financing for the three months ended in Mar. 2022 was $0.0 Mil. Guardant Health received $0.0 Mil on other financial activities.
Thank you for viewing the detailed overview of Guardant Health's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Talasaz Amirali | director, officer: Chairman, President and COO | 18 ISABELLA AVENUE ATHERTON CA 94027 |
Kaul Samir | director | C/O KHOSLA VENTURES 3000 SAND HILL ROAD, BLDG. 3, SUITE 170 MENLO PARK CA 94025 |
Meresman Stanley J | director | 2071 HUNTINGTON LANE LOS ALTOS CA 94024 |
Svf Bluebird (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Svf Enterprise (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Sb Investment Advisers (uk) Ltd | 10 percent owner | 69 GROSVENOR STREET LONDON X0 W1K 3JP |
Softbank Vision Fund (aiv M1) L.p. | 10 percent owner | 251 LITTLE FALLS DRIVE WILMINGTON DE 19808 |
Svf Endurance (cayman) Ltd | 10 percent owner | C/O WALKERS CORPORATE LIMITED 27 HOSPITAL ROAD GEORGE TOWN E9 KY1-9008 |
Clark Ian T | director | SOLAZYME, INC. 225 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080 |
Eltoukhy Helmy | director, officer: Chief Executive Officer | 2 BARRY LANE ATHERTON CA 94027 |
Bertocci Derek A | officer: Chief Financial Officer | 3070 ORCHARD DRIVE SAN JOSE CA 95134 |
Saia John G. | officer: See Remarks | C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY CA 94063 |
Gadde Vijaya | director | C/O TWITTER INC 1355 MARKET STREET SUITE 900 SAN FRANCISCO CA 94103 |
Jallal Bahija | director | 120 MONUMENT CIRCLE INDIANAPOLIS IN 46204 |
Nishar Dipchand | director | C/O LINKEDIN CORPORATION 2029 STIERLIN COURT MOUNTAIN VIEW CA 94043 |
From GuruFocus
Other Sources
By Seekingalpha 2022-01-24
By Seekingalpha 2021-11-04
By Seekingalpha 2022-01-03
By Fool 2022-03-08
By Fool 2022-03-18
By Fool 2021-10-01
By Zacks 2022-02-11
By Zacks 2022-01-27
By Zacks 2022-02-01
By Zacks 2022-01-26
By Zacks 2022-02-03
By Zacks 2022-01-28
By Fool 2022-01-12